121 related articles for article (PubMed ID: 29320752)
1. The value of detection of S100A8 and ASAH1 in predicting the chemotherapy response for breast cancer patients.
Li YH; Liu HT; Xu J; Xing AY; Zhang J; Wang YW; Yin G; Gao P
Hum Pathol; 2018 Apr; 74():156-163. PubMed ID: 29320752
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
3. [Effect of neoadjuvant chemotherapy on histologic grade and expression of biological markers in breast cancer].
Yin HF; Wang YH; Qin XQ; Zhang H; Li T; Ye JM; Liu YH
Zhonghua Zhong Liu Za Zhi; 2009 Nov; 31(11):858-62. PubMed ID: 20137353
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
Chen Y; Song J; Jiang Y; Yu C; Ma Z
Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of histopathologic changes and expression of biomarkers in breast carcinoma before and after neoadjuvant chemotherapy].
Zheng S; Zhang BL; Xiao T; Zou SM; Xue LY; Luo W; Guo L; Liu XY; Lü N
Zhonghua Bing Li Xue Za Zhi; 2011 Jul; 40(7):465-70. PubMed ID: 22088373
[TBL] [Abstract][Full Text] [Related]
6. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
7. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
[TBL] [Abstract][Full Text] [Related]
8. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
9. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
10. Predicting Non-sentinel Lymph Node Metastases in Patients with a Positive Sentinel Lymph Node After Neoadjuvant Chemotherapy.
Barron AU; Hoskin TL; Boughey JC
Ann Surg Oncol; 2018 Oct; 25(10):2867-2874. PubMed ID: 29956095
[TBL] [Abstract][Full Text] [Related]
11. [Expression of PTEN, p53 and EGFR in the molecular subtypes of breast carcinoma and
the correlation among them].
Li X; Wang Q; Fu L; Liu M; Yu X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Sep; 40(9):973-8. PubMed ID: 26408616
[TBL] [Abstract][Full Text] [Related]
12. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
De La Cruz LM; Harhay MO; Zhang P; Ugras S
Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
[TBL] [Abstract][Full Text] [Related]
13. Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer.
Mercogliano MF; Inurrigarro G; De Martino M; Venturutti L; Rivas MA; Cordo-Russo R; Proietti CJ; Fernández EA; Frahm I; Barchuk S; Allemand DH; Figurelli S; Deza EG; Ares S; Gercovich FG; Cortese E; Amasino M; Guzmán P; Roa JC; Elizalde PV; Schillaci R
BMC Cancer; 2017 Dec; 17(1):895. PubMed ID: 29281999
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response.
Mohammed AA; Elsayed FM; Algazar M; Rashed HE; Anter AH
Asian Pac J Cancer Prev; 2020 Feb; 21(2):563-568. PubMed ID: 32102539
[TBL] [Abstract][Full Text] [Related]
15. An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy.
Zhang J; Wang Y; Yin Q; Zhang W; Zhang T; Niu Y
Int J Clin Exp Pathol; 2013; 6(7):1380-91. PubMed ID: 23826420
[TBL] [Abstract][Full Text] [Related]
16. Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer.
Asano Y; Kashiwagi S; Goto W; Kurata K; Noda S; Takashima T; Onoda N; Tanaka S; Ohsawa M; Hirakawa K
Br J Surg; 2016 Jun; 103(7):845-54. PubMed ID: 26953091
[TBL] [Abstract][Full Text] [Related]
17. S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast.
Arai K; Takano S; Teratani T; Ito Y; Yamada T; Nozawa R
Curr Cancer Drug Targets; 2008 Jun; 8(4):243-52. PubMed ID: 18537548
[TBL] [Abstract][Full Text] [Related]
18. FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients.
Xu C; Wei Q; Guo J; Zhou JC; Mei J; Jiang ZN; Shen JG; Wang LB
Ann Surg Oncol; 2015; 22(6):2034-9. PubMed ID: 25707489
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
20. Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer?
Uematsu T; Kasami M; Watanabe J; Takahashi K; Yamasaki S; Tanaka K; Tadokoro Y; Ogiya A
Breast Cancer; 2011 Oct; 18(4):309-13. PubMed ID: 20574730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
